Description: BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is based in Manchester, the United Kingdom.
Home Page: www.bivictrix.com
BVX Technical Analysis
Bio Hub
Macclesfield,
SK10 4TG
United Kingdom
Phone:
Officers
| Name | Title |
|---|---|
| Ms. Tiffany Jane Thorn BSc. MSc., M.Sc. | CEO & Exec. Director |
| Mr. Glyn Baker | Chief Financial Officer |
| Ms. Laura Brogden | Exec. Officer |
| Simon Wallwork | Sec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2252 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |